SARS-CoV-2-induced senescence as a potential therapeutic target

Mary Denholm [1,2], Robert C. Rintoul [3,4] and Daniel Muñoz-Espín [1,4]

[1]Early Cancer Institute, Dept of Oncology, University of Cambridge, Cambridge, UK. [2]Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK. [3]Royal Papworth Hospital NHS Foundation Trust, Cambridge, UK. [4]Cancer Research UK Cambridge Centre Thoracic Cancer Programme, Cambridge, UK.

Corresponding author: Daniel Muñoz-Espín (dm742@cam.ac.uk)

Shareable abstract (@ERSpublications)
Long implicated in the pathology of ageing, cancer and many other systemic diseases, cellular senescence is now emerging as a key factor in the pathogenesis of severe COVID-19, with implications for other viral illnesses. https://bit.ly/3bbmOuT

Cite this article as: Denholm M, Rintoul RC, Muñoz-Espín D. SARS-CoV-2-induced senescence as a potential therapeutic target. *Eur Respir J* 2022; 60: 2201101 [DOI: 10.1183/13993003.01101-2022].

Received: 27 May 2022
Accepted: 17 June 2022

The global coronavirus disease 2019 (COVID-19) pandemic has caused major morbidity, mortality and socioeconomic disruption on an individual and collective level. Over 6 million COVID-19-related deaths have been reported, with total case numbers now well over 500 million worldwide [1]. Whilst the prompt and efficient design of effective vaccines has restored varying degrees of normal activity to some parts of world, the effects of the pandemic will be long in duration and far-reaching.